免疫功能低下的肾移植患者感染2019冠状病毒病的管理
该文回顾性分析2021年10月新疆维吾尔自治区霍尔果斯定点医院收治的1例肾移植术后3年中年男性COVID-19患者的诊治过程。患者以中低热起病,伴咳嗽、乏力,胸部CT示双肺胸膜下多发磨玻璃影,以双下肺为主,逐渐加重至「白肺」,早期出现肾功能和心功能不全。治疗中减少免疫抑制剂并增加糖皮质激素剂量,因肾功能不全和高钾血症行透析3次,口服阿比多尔和连花清瘟胶囊抗病毒抗感染,使用特异性免疫球蛋白和COVID-19恢复期血浆增强免疫力,患者最终临床治愈。作者认为肾移植受者COVID-19临床表现和诊断与其他人群无显著差异,但免疫抑制宿主更易发生器官功能障碍,免疫抑制剂和糖皮质激素调整、呼吸支持、抗生素选择、器官保护、营养支持及中医药干预等需进一步讨论。
要点
- 肾移植受者感染COVID-19的临床表现和诊断与其他人群无显著差异,但免疫抑制宿主更易出现器官功能障碍。
- 该例肾移植术后3年中年男性以中低热起病,伴咳嗽、乏力,胸部CT示双肺胸膜下多发磨玻璃影、以双下肺为主,逐渐加重至「白肺」。
- 治疗中减少免疫抑制剂并增加糖皮质激素剂量;早期因肾功能不全和高钾血症行透析3次。
- 给予口服阿比多尔和连花清瘟胶囊抗病毒抗感染,并使用特异性免疫球蛋白和COVID-19恢复期血浆增强免疫力,患者最终临床治愈。
- 作者认为肾移植受者重型COVID-19的免疫抑制剂和糖皮质激素调整、呼吸支持、抗生素选择、器官保护、营养支持及中医药干预需进一步讨论。
适用人群与场景
- 肾移植术后3年的中年男性受者,感染COVID-19,以中低热起病伴咳嗽、乏力,收治于定点医院。
处置流程与药物剂量
- 减少免疫抑制剂并增加糖皮质激素剂量。
- 早期因肾功能不全和高钾血症行透析3次。
- 口服阿比多尔和连花清瘟胶囊抗病毒抗感染。
- 使用特异性免疫球蛋白和COVID-19恢复期血浆增强免疫力。
红旗征与不能漏的情况
- 胸部CT示双肺胸膜下多发磨玻璃影、以双下肺为主,逐渐加重至「白肺」。
- 早期出现肾功能和心功能不全。
- 肾功能不全和高钾血症,需透析治疗。
研究设计与关键结果
- 回顾性分析1例肾移植术后3年中年男性COVID-19患者的诊治过程,以中低热起病伴咳嗽、乏力,胸部CT示双肺胸膜下多发磨玻璃影、以双下肺为主并逐渐加重至「白肺」,早期出现肾功能和心功能不全。
- 治疗中减少免疫抑制剂并增加糖皮质激素剂量,早期因肾功能不全和高钾血症行透析3次,口服阿比多尔和连花清瘟胶囊,使用特异性免疫球蛋白和COVID-19恢复期血浆,患者最终临床治愈。
证据类型、等级与局限
- 证据类型:病例报告(回顾性分析1例肾移植受者COVID-19诊治过程)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为肾移植受者COVID-19临床表现和诊断与其他人群无显著差异,但免疫抑制宿主更易发生器官功能障碍。
- 作者认为肾移植受者重型COVID-19的免疫抑制剂和糖皮质激素调整、呼吸支持、抗生素选择、器官保护、营养支持及中医药干预需进一步讨论。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To analyze the treatment process of a renal transplant patient infected with coronavirus disease 2019 (COVID-19), and discuss the management strategy for the immunocompromised hosts.
METHODS: The diagnosis and treatment of a case of transplant patients with COVID-19 admitted to Horgos designated hospital of Xinjiang Uygur Autonomous Region in October 2021 were reviewed. The medical history and laboratory and imaging examination treatment and outcome of this case were analyzed.
RESULTS: The recipient was a middle-aged male with a time from renal transplantation of 3 years. The onset was moderate to low fever, accompanied by cough and fatigue. Chest CT showed multiple ground glass shadows under the pleura of both lungs, mainly in both lower lungs, gradually worsening until "white lung" appeared, with early renal and cardiac insufficiency. In the course of treatment, immunosuppressants were reduced and the dosage of glucocorticoid was increased. In the early stage, due to renal insufficiency and hyperkalemia, dialysis was conducted for 3 times. Oral abidol and Lianhua Qingwen capsule were given as antiviral and anti-infection treatment. Special immunoglobulin and convalescent plasma of COVID-19 were used to boost the immunity of patients. The patient was eventually clinically cured.
CONCLUSIONS: The clinical manifestations and diagnosis of COVID-19 for the kidney transplantation recipient are not significantly different from other populations, but immunocompromised hosts are more likely to suffer from organ dysfunction. The adjustment of immunosuppressants and glucocorticoids, respiratory support, selection of antibiotics, organ protection, nutritional support and traditional Chinese medicine intervention in the treatment of renal transplant recipients with severe COVID-19 need further discussion.
参考来源
- Hu R, Qiu W, Zhao X, et al. [Management of immunocompromised renal transplant patients infected with coronavirus disease 2019]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 35728850. doi:10.3760/cma.j.cn121430-20220315-00246
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。